Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IK-595 in RAS/RAF-altered advanced solid tumors
NCT06270082Phase 1Terminated
- Sponsor
- ImageneBio
- Start
- Dec 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IK-595 in colorectal cancer (CRC), pancreatic cancer (PC), Malignant Melanoma (MM) and 6 more, sponsored by ImageneBio. Primary endpoints: Treatment-Emergent Adverse Events at 36 months, Dose Limiting Toxicities at 30 days and 2 more. Started Dec 2023; status: terminated.
02
Drugs
IK-595
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)Malignant Melanoma (MM)non-small cell lung cancer (NSCLC)thyroid carcinoma (TC)
Beyond the preview
Go deeper on NCT06270082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06270082.